Todd Lorenz has more than 25 years of experience in life sciences intellectual property law, and is known for developing comprehensive and effective patent portfolios that stand up to challenge and survive the test of time. Todd’s practice encompasses strategic patent prosecution and counseling, along with transactional due diligence, opinion work, licensing and litigation, and he works closely with his clients throughout their product life cycle(s) to ensure that the corresponding patents mature worldwide with strong and commercially relevant claims.

He advises universities, clinical research centers, and emerging and established life science companies on all aspects of domestic and international patent procurement and enforcement in a broad range of technical areas including drug development (biologics and pharmaceuticals), drug delivery, digital health, diagnostics, industrial biotechnology and laboratory instrumentation.

Todd’s patent drafting and prosecution experience encompasses a wide variety of technical disciplines, including proteins, peptides, antibodies and antibody engineering, ADCs, T&NK cell therapies (e.g., CAR-T, NK, TaNK, CAR-NK), stem cells and stem cell therapies, gene therapy, genetic engineering (including CRISPR), transgenic animals, small molecules (e.g., toxins, biguanides), drug delivery (e.g., polymers, liposomes, chitosan, enteric coatings), synthetic tissues, 3D bioprinting, medical devices, laboratory hardware, protein purification and separation, and digital health platforms. The combined value of his portfolio acquisitions to date is well in excess of US$3 billion, including SangStat Medical Corporation (immunosuppressants), Oculex Pharmaceuticals (ocular drug delivery), U.C. Berkeley/Medarex (CTLA-4 Blockade/ipilimumab), Open Monoclonal Technologies (transgenic animals) and Kairos Therapeutics (antibody-drug conjugates).

As co-founder and CEO of Myocept Inc., a biotech company developing a new generation of transcutaneous therapeutics, he is particularly attuned to the needs and challenges of emerging companies. With an academic background in biology and biomedical engineering at Rensselaer Polytechnic Institute, clinical research experience in cancer immunotherapy at Harvard Medical School, and practical hands-on experience in drug development, formulation and commercialization at Myocept Inc., Todd brings a wide range of capabilities throughout the biotechnology and pharmaceutical arts to his law practice.

Award Mouse thought multimedia interface book medal screen monitor
  • Patented CTLA-4 Blockade on behalf of 2018 Nobel laureate James P. Allison and his colleagues at U.C. Berkeley, leading to the development of the first immune checkpoint inhibitor for oncology.
  • Patented a series of fully human monoclonal antibody production platforms (OmniRat®, OmniFlic®, OmniMouse® and UniRat®) for a serial entrepreneur in the recombinant animal engineering space; now out-licensed to more than 35 companies worldwide.
  • Managing and expanding the worldwide patent portfolio for a US$2 billion/year antibody therapeutic for treating multiple sclerosis and Crohn’s disease for a major biotech client.
  • Developing and implementing the worldwide patent portfolio for an emerging cell therapy company focused on allogeneic CAR-T cells.
  • Developing and implementing the foundational patent portfolio for a cutting-edge startup biotech company creating synthetic tissue structures for human transplantation by way of 3D-bioprinting.
  • Advising a revolutionary digital therapeutics company on IP strategy to protect their clinically successful behavioral modification technology platform for treating metabolic disorders.
  • Advising a nascent RNAi therapeutics company on the in-licensing, implementation and expansion of their foundational university IP portfolio in the CNS space.


  • Boston University School of Law, J.D., cum laude, 1993
  • Rensselaer Polytechnic Institute, B.S., 1988


  • California, 1995
  • U.S. Patent and Trademark Office


  • U.S. Ct. of App., Federal Circuit
  • U.S. Ct. of App., Ninth Circuit

{{}} {{insights.type}} {{insights.contentTypeTag}}
{{blog.title}} {{blog.source}}

  • Speaker, “Translation of Bioprinted Tissues into the Clinic,” Printing the Future of Therapeutics in 3D, Peter Wall Institute for Advanced Studies, Vancouver, BC, Canada, May 6-8, 2019.

Award Mouse thought multimedia interface book medal screen monitor